CS
YMAB

Credit Suisse’s Y-mAbs Therapeutics YMAB Stock Holding History

Credit Suisse’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,704
Closed -$116K – 3768
2022
Q4 		$116K Sell
23,704
-1,273
-5% -$9.25K ﹤0.01% 3307
2022
Q3 		$360K Buy
24,977
+4,053
+19% +$67.1K ﹤0.01% 2992
2022
Q2 		$317K Buy
20,924
+1,659
+9% +$19.4K ﹤0.01% 3133
2022
Q1 		$228K Buy
19,265
+1,199
+7% +$12.3K ﹤0.01% 3339
2021
Q4 		$294K Buy
18,066
+1,124
+7% +$24K ﹤0.01% 4119
2021
Q3 		$483K Buy
16,942
+1,375
+9% +$43.3K ﹤0.01% 3820
2021
Q2 		$527K Buy
15,567
+851
+6% +$27.3K ﹤0.01% 3808
2021
Q1 		$445K Sell
14,716
-13,223
-47% -$542K ﹤0.01% 3845
2020
Q4 		$1.38M Sell
27,939
-1,537
-5% -$71.1K ﹤0.01% 3096
2020
Q3 		$1.13M Sell
29,476
-7,680
-21% -$306K ﹤0.01% 2839
2020
Q2 		$1.6M Buy
37,156
+15,982
+75% +$604K ﹤0.01% 2558
2020
Q1 		$553K Sell
21,174
-10,071
-32% -$292K ﹤0.01% 3051
2019
Q4 		$976K Buy
31,245
+21,830
+232% +$646K ﹤0.01% 3143
2019
Q3 		$246K Buy
+9,415
New +$241K ﹤0.01% 3787

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Credit Suisse's YMAB Position: Q1 2023 in Review

Credit Suisse sold out of Y-mAbs Therapeutics (YMAB) in Q1 2023, closing a stake of 23,704 shares — an estimated $116K sold.

Credit Suisse first reported a position in YMAB in Q3 2019 and held it in 14 quarters. The position peaked at $1.6M in Q2 2020. 85 funds tracked by Wall St. Rank hold YMAB as of Q1 2023.

  • Credit Suisse reported no remaining Y-mAbs Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 23,704 Y-mAbs Therapeutics shares in Q1 2023, an estimated $116K.
  • Credit Suisse first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 14 quarters.
  • Credit Suisse's Y-mAbs Therapeutics position peaked at $1.6M in Q2 2020.
  • 85 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.